An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy-Reference-Cited by-同舟云学术

An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy

Published:2021-02-13 Issue:3 Volume:14 Page:333-340
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Rau Monika¹,Geier Andreas¹

Affiliation:

1. Division of Hepatology, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2021.1884068

Reference57 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

3. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

4. US Food and Drug Administration. Noncirrhotic Non-Alcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. [cited 2021 Jan 23]. https://wwwfdagov/media/119044/download.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current strategies for nonalcoholic fatty liver disease treatment (Review);International Journal of Molecular Medicine;2024-08-08

2. Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo;Scientific Reports;2024-07-23

3. Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH;European Journal of Medicinal Chemistry;2024-04

4. Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression;Liver Research;2023-06

5. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets;Journal of Advanced Research;2023-06